Item 2.02 Results of Operations and Financial Condition.

On January 10, 2022, Douglas S. Ingram, President and Chief Executive Officer of Sarepta Therapeutics, Inc. (the "Company") disclosed certain preliminary financial information for the year ended December 31, 2021 during the Company's presentation at the 40th Annual J.P. Morgan Healthcare Conference (the "Conference") and in discussions with third parties at the Conference. Specifically, the Company disclosed its (unaudited) cash position of approximately $2.1 billion as of December 31, 2021 and that the Company generated approximately $178.7 million in revenue (unaudited) in the fourth quarter ended December 31, 2021 and approximately $612 million in revenue (unaudited) in the year ended December 31, 2021, each from sales of EXONDYS 51® (eteplirsen) Injection, VYONDYS 53® (golodirsen) Injection and AMONDYS 45® (casimersen) Injection.

The information in this Item 2.02 is unaudited and preliminary, and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2021 and its results of operations for the three months and year ended December 31, 2021. The audit of the Company's financial statements for the year ended December 31, 2021 is ongoing and could result in changes to the information in this Item 2.02.

Item 7.01 Regulation FD Disclosure.

The disclosure in Item 2.02 above is hereby incorporated by reference into this Item 7.01.

On January 10, 2022, Mr. Ingram also presented at the Conference topline results from part two of Study 102 evaluating SRP-9001, the Company's investigational gene therapy for the treatment of Duchenne muscular dystrophy. The Company issued a press release disclosing such information. Copies of the press release and the slides presented by Mr. Ingram at the Conference on January 10, 2022 are furnished with this report as Exhibits 99.1 and 99.2, respectively.

The information in this report, including Exhibits 99.1 and 99.2 attached hereto, is furnished pursuant to Items 2.02 and 7.01 and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Items 2.02 and 7.01 of this report.

Item 9.01 Financial Statements and Exhibits.



(d)
Exhibits



Exhibit
Number                                   Description
 99.1       Press release dated January 10, 2022: Sarepta Therapeutics' Gene

Therapy SRP-9001 Shows Statistically Significant Functional Improvements

Compared to Pre-specified Matched External Control in Part 2 of Study

SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. Presentation at the 40th Annual J.P. Morgan

99.2 Healthcare Conference, dated January 10, 2022

104 The cover page from this Current Report on Form 8-K of Sarepta

Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses